HUP0102240A3 - Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases - Google Patents
Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinasesInfo
- Publication number
- HUP0102240A3 HUP0102240A3 HU0102240A HUP0102240A HUP0102240A3 HU P0102240 A3 HUP0102240 A3 HU P0102240A3 HU 0102240 A HU0102240 A HU 0102240A HU P0102240 A HUP0102240 A HU P0102240A HU P0102240 A3 HUP0102240 A3 HU P0102240A3
- Authority
- HU
- Hungary
- Prior art keywords
- medicament
- manufacture
- cyclin dependent
- dependent kinases
- inhibit cyclin
- Prior art date
Links
- 108091007914 CDKs Proteins 0.000 title 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98109845A EP0966963A1 (en) | 1998-05-29 | 1998-05-29 | Use of indigoid bisindole derivatives as CDK1 inhibitors |
| EP99105693 | 1999-03-19 | ||
| PCT/EP1999/003625 WO1999062503A2 (en) | 1998-05-29 | 1999-05-26 | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0102240A2 HUP0102240A2 (hu) | 2001-11-28 |
| HUP0102240A3 true HUP0102240A3 (en) | 2003-05-28 |
Family
ID=26149292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102240A HUP0102240A3 (en) | 1998-05-29 | 1999-05-26 | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1079826B1 (hu) |
| JP (1) | JP2002516851A (hu) |
| KR (1) | KR20010078722A (hu) |
| AT (1) | ATE233560T1 (hu) |
| AU (1) | AU762830B2 (hu) |
| BR (1) | BR9910810A (hu) |
| CA (1) | CA2333661A1 (hu) |
| DE (1) | DE69905712T2 (hu) |
| DK (1) | DK1079826T3 (hu) |
| ES (1) | ES2194468T3 (hu) |
| HU (1) | HUP0102240A3 (hu) |
| IL (1) | IL139914A0 (hu) |
| NO (1) | NO20006027L (hu) |
| WO (1) | WO1999062503A2 (hu) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| ATE427746T1 (de) * | 1999-04-12 | 2009-04-15 | Heinz Herbert Fiebig | 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren |
| SK14272001A3 (sk) | 1999-04-12 | 2002-05-09 | Gerhard Eisenbrand | Indigoidné bisindolové deriváty |
| AU2002213132A1 (en) * | 2000-10-10 | 2002-04-22 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
| DE10053474A1 (de) * | 2000-10-24 | 2002-05-02 | Schering Ag | Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung |
| DE10061162A1 (de) * | 2000-11-30 | 2002-07-11 | Schering Ag | Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung |
| WO2002059123A2 (en) * | 2000-12-18 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds |
| FR2821358B1 (fr) * | 2001-02-27 | 2006-04-07 | Aventis Pharma Sa | Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique |
| DE10114138C2 (de) * | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
| DE10125763A1 (de) * | 2001-05-17 | 2002-11-28 | Schering Ag | Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
| US6566341B1 (en) * | 2001-12-13 | 2003-05-20 | Natrogen Therapeutics, Inc. | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| AU2002357191A1 (en) * | 2001-12-13 | 2003-06-30 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| MXPA04009434A (es) * | 2002-04-03 | 2005-01-25 | Allergan Inc | (3z)-3- (3 -hidroisobenzofuran- 1-iliden) -1, 3-dihidro- 2h-indol -2-onas como inhibidores de cinasa. |
| CN1199946C (zh) * | 2002-10-29 | 2005-05-04 | 无锡杰西医药科技有限公司 | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| EP1746887A1 (en) * | 2004-05-12 | 2007-01-31 | Bayer CropScience GmbH | Plant growth regulation |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| CN1329376C (zh) * | 2005-09-19 | 2007-08-01 | 无锡杰西医药科技有限公司 | 一种n（1）－烃基－3′－肟基靛玉红衍生物（i）的制备方法及其医学应用 |
| JP4587961B2 (ja) * | 2006-01-16 | 2010-11-24 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| EP2199292A1 (en) | 2008-12-22 | 2010-06-23 | Technische Universität Kaiserlautern | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| WO2010072399A1 (en) | 2008-12-22 | 2010-07-01 | Gerhard Eisenbrand | 7-azaindirubins, 7'azaindirubins, 7,7'-diazaindirubins and the corresponding 3'-oxime ether derivatives thereof, their production and use as a medicament |
| FR2945747A1 (fr) | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire |
| FR2952818B1 (fr) * | 2009-11-23 | 2013-05-31 | Oreal | Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| US8524121B2 (en) * | 2012-01-27 | 2013-09-03 | Xerox Corporation | Bi-indoline-dithione polymers |
| AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| CN113773243B (zh) * | 2021-09-01 | 2023-01-06 | 大连理工大学 | 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法 |
| CN118317948A (zh) | 2021-10-08 | 2024-07-09 | 阿佐拉治疗股份有限公司 | 芳烃受体激动剂的衍生物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| ATE308520T1 (de) * | 1996-08-23 | 2005-11-15 | Sugen Inc | Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten |
-
1999
- 1999-05-26 CA CA002333661A patent/CA2333661A1/en not_active Abandoned
- 1999-05-26 DK DK99926420T patent/DK1079826T3/da active
- 1999-05-26 JP JP2000551759A patent/JP2002516851A/ja active Pending
- 1999-05-26 DE DE69905712T patent/DE69905712T2/de not_active Expired - Fee Related
- 1999-05-26 WO PCT/EP1999/003625 patent/WO1999062503A2/en not_active Application Discontinuation
- 1999-05-26 IL IL13991499A patent/IL139914A0/xx unknown
- 1999-05-26 AU AU43687/99A patent/AU762830B2/en not_active Ceased
- 1999-05-26 HU HU0102240A patent/HUP0102240A3/hu unknown
- 1999-05-26 AT AT99926420T patent/ATE233560T1/de not_active IP Right Cessation
- 1999-05-26 EP EP99926420A patent/EP1079826B1/en not_active Expired - Lifetime
- 1999-05-26 BR BR9910810-0A patent/BR9910810A/pt not_active IP Right Cessation
- 1999-05-26 ES ES99926420T patent/ES2194468T3/es not_active Expired - Lifetime
- 1999-05-26 KR KR1020007013499A patent/KR20010078722A/ko not_active Application Discontinuation
-
2000
- 2000-11-28 NO NO20006027A patent/NO20006027L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999062503A3 (en) | 2000-01-27 |
| NO20006027L (no) | 2001-01-22 |
| AU4368799A (en) | 1999-12-20 |
| AU762830B2 (en) | 2003-07-03 |
| WO1999062503A2 (en) | 1999-12-09 |
| ES2194468T3 (es) | 2003-11-16 |
| IL139914A0 (en) | 2002-02-10 |
| EP1079826B1 (en) | 2003-03-05 |
| JP2002516851A (ja) | 2002-06-11 |
| BR9910810A (pt) | 2001-02-13 |
| EP1079826A2 (en) | 2001-03-07 |
| DE69905712T2 (de) | 2004-01-29 |
| DK1079826T3 (da) | 2003-06-23 |
| CA2333661A1 (en) | 1999-12-09 |
| KR20010078722A (ko) | 2001-08-21 |
| ATE233560T1 (de) | 2003-03-15 |
| NO20006027D0 (no) | 2000-11-28 |
| DE69905712D1 (de) | 2003-04-10 |
| HUP0102240A2 (hu) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0102240A3 (en) | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases | |
| HUP0102556A3 (en) | Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds | |
| IL144668A (en) | Use of a 4-h-1-benzopyran-4-one derivative for the preparation of a medicament for inhibiting smooth muscle cell proliferation | |
| HUP0200310A3 (en) | Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compounds | |
| EP1115422A4 (en) | USE OF NON-PEPTIDYLIC COMPOUNDS FOR THE TREATMENT OF INSULIN-RELATED CONDITIONS | |
| AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
| IL143979A0 (en) | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | |
| HUP0200819A3 (en) | Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk | |
| HU9800535D0 (en) | Use of pyrimidine derivatives for producing pharmaceutical compositions for preventing tumor | |
| HU9800291D0 (en) | Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus | |
| IL138645A0 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedghog signalling pathways | |
| HUP0200441A3 (en) | Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds | |
| PL357780A1 (en) | Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain | |
| AU2177001A (en) | Use of indirubine derivatives for making medicines | |
| ZA983602B (en) | Use of tetrahydropyridine derivatives for the preparation of drugs for the treatment of diseases which cause demyelination | |
| AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
| CA2369626A1 (en) | Use of cell membrane penetrating indigoid bisindole derivatives | |
| HUP0102436A3 (en) | Use of reboxetin for preparation of medicament for nervous disorders | |
| HK1053424A1 (en) | The use of exemestane for the preparation of a medicament for the first-line treatment of breast cancer | |
| HUP0201667A2 (en) | Oral form of administration | |
| IL147496A0 (en) | Preparation of a therapeutic composition | |
| EP1003516A4 (en) | METHOD FOR THE ADMINISTRATION OF CAMPTOTHECIN COMPOSITIONS FOR CANCER TREATMENT WITH REDUCED SIDE EFFECTS | |
| IL149534A0 (en) | Preparation of 3-substituted-4-arylquinolin-2-one derivatives | |
| PL352409A1 (en) | Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane | |
| HUP0203900A3 (en) | Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |